Litigation Fears Prompt Generic Backlash to FDA’s Proposed Labeling Rule

Drug Industry Daily
A A
A group of generic drugmakers is proposing the FDA take the lead on initiating drug labeling changes prompted by adverse events, rather than relying on individual companies to initiate the changes.

To View This Article:

Login

Subscribe To Drug Industry Daily